Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05655949 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Collaborators: 3 to 2v12 See this version in full on ClinicalTrials.gov ↗
  2. Re-verified, no change to tracked fieldsv11
  3. Start date changed from estimate of Feb 2024 to Feb 13, 2024v10
  4. Primary completion date: Dec 1, 2024 to Dec 1, 2026 Start date: Dec 2023 to Feb 2024v9 Show 1 more changeShow less
    • Start date: Dec 2023 to Feb 2024
  5. Start date: Sep 1, 2023 to Dec 2023v8
Show 6 earlier versionsHide 6 earlier versions
  1. Trial status: Not Yet Recruiting to Recruiting Start date: Aug 1, 2023 to Sep 1, 2023 · Site details revisedv7 Show 2 more changesShow less
    • Start date: Aug 1, 2023 to Sep 1, 2023
    • Site details revised
  2. Start date: Jun 1, 2023 to Aug 1, 2023v6
  3. Lead sponsor: Dana-Farber Cancer Institute to Beth Israel Deaconess Medical Center Collaborators: 2 to 3v5 Show 1 more changeShow less
    • Collaborators: 2 to 3

    See this version in full on ClinicalTrials.gov ↗

  4. Start date: Apr 1, 2023 to Jun 1, 2023v4
  5. Re-verified, no change to tracked fieldsv3
  6. Start date: Dec 2022 to Apr 1, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: * Y-90 (a type of radiation microsphere bead) * Durvalumab (a type of immunotherapy) * Gemcitabine (a type of chemotherapy) * Cisplatin (a type of chemotherapy)
Trial Details
NCT Number NCT05655949
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: Sirtex Medical, Dana-Farber Cancer Institute
Conditions Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Metastatic Intrahepatic Cholangiocarcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov